Patrick Dorr

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density
    Samantha Willey
    Center for AIDS Research, Program in Molecular Medicine, Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Biotech II, 373 Plantation St, Worcester, MA 01605, USA
    Antiviral Res 68:96-108. 2005
  2. doi request reprint CCR5 inhibitors in HIV-1 therapy
    Patrick Dorr
    Senior Principal Scientist Pfizer Global R and D, Primary Pharmacology, Sandwich Laboratories, CT13 9NJ, Kent, UK 44 0 1304648034 44 0 1304651817
    Expert Opin Drug Discov 3:1345-61. 2008
  3. pmc Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
    Patrick Dorr
    Discovery Biology, Pfizer Global Research and Development Sandwich Laboratories, Kent CT13 9NJ, United Kingdom
    Antimicrob Agents Chemother 49:4721-32. 2005
  4. pmc Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
    Mike Westby
    Globel Research and Development, Pfizer Ltd, Sandwich Labs, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
    J Virol 81:2359-71. 2007
  5. doi request reprint CCR5 pharmacology methodologies and associated applications
    Roy Mansfield
    Pfizer GRD Sandwich Laboratories, Sandwich, Kent, United Kingdom
    Methods Enzymol 460:17-55. 2009

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density
    Samantha Willey
    Center for AIDS Research, Program in Molecular Medicine, Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Biotech II, 373 Plantation St, Worcester, MA 01605, USA
    Antiviral Res 68:96-108. 2005
    ..The extent of inhibition was dependent on cell type and on cell surface CCR5 concentration. Our results underscore the potential of CCR5 inhibitors for clinical development...
  2. doi request reprint CCR5 inhibitors in HIV-1 therapy
    Patrick Dorr
    Senior Principal Scientist Pfizer Global R and D, Primary Pharmacology, Sandwich Laboratories, CT13 9NJ, Kent, UK 44 0 1304648034 44 0 1304651817
    Expert Opin Drug Discov 3:1345-61. 2008
    ..The status and expert opinion of CCR5 antagonists for the treatment of HIV-1 infection are detailed...
  3. pmc Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
    Patrick Dorr
    Discovery Biology, Pfizer Global Research and Development Sandwich Laboratories, Kent CT13 9NJ, United Kingdom
    Antimicrob Agents Chemother 49:4721-32. 2005
    ..Clinical trials are ongoing to further investigate the potential of using maraviroc for the treatment of HIV-1 infection and AIDS...
  4. pmc Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
    Mike Westby
    Globel Research and Development, Pfizer Ltd, Sandwich Labs, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
    J Virol 81:2359-71. 2007
    ..This hypothesis was further corroborated by the observation that a high concentration of maraviroc blocks the activity of aplaviroc against maraviroc-resistant virus...
  5. doi request reprint CCR5 pharmacology methodologies and associated applications
    Roy Mansfield
    Pfizer GRD Sandwich Laboratories, Sandwich, Kent, United Kingdom
    Methods Enzymol 460:17-55. 2009
    ....